Does reimbursement influence chemotherapy treatment for cancer patients?
Does reimbursement influence chemotherapy treatment for cancer patients?
复制标题
DOI：
10.1377/hlthaff.25.2.437
复制
发表时间：
2006-03-01
期刊：
影响因子：
9.7
通讯作者：
Newhouse, JP
中科院分区：
文献类型：
--
作者：
Jacobson, M;O'Malley, AJ;Newhouse, JP
在2003年的《联邦医疗保险处方药、改善和现代化法案》(MMA)之前，联邦医疗保险向医生报销化疗药物的费率大大超过了医生购买这些药物的费用。我们研究了1995至1998年间，65岁以上的老年转移性肺癌、乳腺癌、结直肠癌或其他胃肠道癌症患者(9,357名患者)接受化疗时，医生报销对化疗的影响。医生对转移性癌症患者进行化疗的决定并没有受到更高报销的显著影响。然而，那些得到更慷慨补偿的提供者给转移性乳腺癌、结直肠癌和肺癌患者开出了更昂贵的化疗方案。
Before the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003, Medicare reimbursed physicians for chemotherapy drugs at rates that greatly exceeded physicians' costs for those drugs. We examined the effect of physician reimbursement on chemotherapy treatment of Medicare beneficiaries older than age sixty-five with metastatic lung, breast, colorectal, or other gastrointestinal cancers between 1995 and 1998 (9,357 patients). A physician's decision to administer chemotherapy to metastatic cancer patients was not measurably affected by higher reimbursement. Providers who were more generously reimbursed, however, prescribed more-costly chemotherapy regimens to metastatic breast, colorectal, and lung cancer patients.